GLP-1
Every GLP-1 claim we've checked against the studies, newest first, each graded from Solid to Debunked by the evidence in people.

Peptides for weight loss: three approved ones cut 8% to 21%
Wegovy, Zepbound and Saxenda cut body weight 8% to 21% in large randomized trials. Retatrutide and research-only vials are not approved.

The best peptides in 2026, ranked by human evidence
Tirzepatide took off 20.9% of body weight in 2,539 adults. We ranked 23 peptides by human trials: 6 work for one use, 9 were never tested for theirs.

Foundayo and the Wegovy pill cut weight 11% to 14% in trials
In trials, the daily pills Foundayo (orforglipron) and the Wegovy pill cut weight 11% to 14%. People who switched from a shot to the pill kept most of their loss.

Retatrutide cut body weight by a quarter in its big trial
In a 2,339-person trial, retatrutide's top dose cut weight by 25% on average, or 28% for those who stayed on it. It hasn't been tested head to head with tirzepatide.

BPC-157 isn't the next Ozempic
GLP-1 peptides cut weight 15% to 28% in big trials. BPC-157 sped healing in rats, but only 31 people have tried it, none against a placebo.

Muscle loss on Ozempic matches any other diet
The claim that 40% of GLP-1 weight loss is muscle mixes up muscle with lean mass. Trial scans show the drugs cost about as much muscle as any weight loss.

